认知衰退诊断中的人工智能:评估尖端技术和方法
Arash Gharehbaghi1, Ankica Babic1,2
1Department of Biomedical Engineering, Linköping University, Linköping, Sweden.
Studies in health technology and informatics
|July 1, 2025
概括
人工智能 (AI) 显示出早期认知衰退 (CD) 诊断的巨大潜力. 使用MRI扫描的机器学习模型达到98%的准确性,而NLP模型在临床前检测时显示75%的准确性.
科学领域:
- 老年学是指老年学的学科.
- 医疗成像医学成像
- 人工智能的人工智能
背景情况:
- 认知衰退 (CD) 是老年人健康的一个重大问题.
- 早期诊断CD对于及时干预和管理至关重要.
- 现有的诊断方法在灵敏度和可访问性方面存在局限性.
研究的目的:
- 对人工智能 (AI) 在早期认知衰退 (CD) 诊断方面的潜力进行范围审查.
- 分析最近人工智能驱动的CD诊断工具的进展.
- 确定关键的方法及其在检测CD的性能.
主要方法:
- 从2020-2025年对同行评审出版物的范围审查.
- 分析使用磁共振成像 (MRI) 和人工智能模型的研究.
- 评估深度学习与临床数据和脑电图 (EEG) 的整合.
- 评估自然语言处理 (NLP) 模型用于CD检测.
主要成果:
- 超过70%的审查研究使用了对AI模型的MRI输入,达到98%的诊断准确度.
- 临床数据和EEG与深度学习的整合显著提高了临床环境中的准确性.
- NLP模型在早期CD检测中显示了75%的准确性,显示了临床前使用的前景.
结论:
- 人工智能,特别是使用MRI和临床数据的深度学习,为早期CD诊断提供了高准确度.
- 在临床前阶段,NLP提供了一种可行的方法来检测CD.
- 建议对人工智能工具进行进一步的研究和整合,以加强老年人医疗保健.
相关概念视频
01:30Cognitive Development During Adulthood
299
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
299
01:20Introduction to Cognitive Psychology
1.0K
Cognitive psychology is the field of psychology dedicated to examining how people think. It attempts to explain how and why we think the way we do by studying the interactions among human thinking, emotion, creativity, language, and problem-solving, as well as other cognitive processes. Cognitive psychology studies how information is processed and manipulated in remembering, thinking, and knowing.
This field emerged in the mid-20th century, following a period dominated by behaviorism, which...
This field emerged in the mid-20th century, following a period dominated by behaviorism, which...
1.0K
01:26Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
01:30Dementia
174
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
174
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
213
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
213